An Analysis of the Long-Term Safety Data of Repeat Administrations of Botulinum Neurotoxin Type A-ABO for the Treatment of Glabellar Lines

Aesthetic Surgery Journal

Volumn 29, Issue 6 SUPPL., 2009, Pages

  Cohen, Joel L ^a   Schlessinger, Joel ^a   Cox, Sue Ellen ^a   Lin, Xiaoming ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; BLEPHAROSPASM; BLURRED VISION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; EYE IRRITATION; EYELID EDEMA; FEMALE; FOLLOW UP; GENDER; GLABELLAR FACIAL LINE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE MASS; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PTOSIS; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; WRINKLE;

AGED; BLEPHAROPTOSIS; BOTULINUM TOXIN TYPE A; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTOXINS; SEX FACTORS; SKIN AGING; TIME FACTORS; TREATMENT OUTCOME;

EID: 71549123989     PISSN: 1090820X     EISSN: 1527330X     Source Type: Journal    
DOI: 10.1016/j.asj.2009.09.003     Document Type: Article

References (12)

1. Piérard G.E., and Lapière C.M. The microanatomical basis of facial frown lines. Arch Dermatol 125 (1989) 1090-1092
2. Ipsen: FDA's first-cycle review of Reloxin extended. Reuters (January 7, 2009). (Accessed March 6, 2009, at http://www.reuters.com/article/pressRelease/idUS197796107-Jan-20091BW20090107.)
3. Brandt F, Swanson N, Baumann L, Huber B. A randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009 June 22 (Epub ahead of print).
4. Rubin M.G., Dover J., Glogau R.G., Goldberg D.J., Goldman M.P., and Schlessinger J. The efficacy and safety of a new U.S. botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol 8 (2009) 439-444
5. Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., and Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51 (2004) 223-233
6. Moy R., Maas C., Monheit G., Huber M.B., and Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 11 (2009) 77-83
7. Monheit G., Carruthers A., Brandt F., and Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33 1 spec no. (2007) S51-S59
8. Kane M.A., Brandt F., Rohrich R.J., Narins R.S., Monheit G.D., and Huber M.B. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg (2009 Jul 28) (Epub ahead of print).
9. Monheit G.D., Cohen J.L., and Reloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol 61 (2009) 421-425
10. Carruthers J.A., Lowe N.J., Menter M.A., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46 (2002) 840-849
11. Botox Cosmetic [package insert] (April 2008), Allergan, Irvine, CA
12. Frampton J.E., and Easthope S.E. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol 4 (2003) 709-725